Heron Therapeutics | HRTX - Cost Of Sales

Stock Price
1.06
Daily Change
-0.08 -6.64%
Monthly
-16.27%
Yearly
-55.30%
Q1 Forecast
1.15

Heron Therapeutics reported $9.46M in Cost of Sales for its fiscal quarter ending in September of 2024.





Cost Of Sales Change Date
ALKERMES USD 46.21M 5.38M Dec/2025
Alnylam Pharmaceuticals USD 267.72M 67.57M Dec/2025
Amarin USD 16.89M 18.51M Mar/2025
ANI Pharmaceuticals USD 122.88M 6.86M Dec/2025
Anika Therapeutics USD 11.49M 35.48M Mar/2025
Eisai JPY 51.08B 5.56B Dec/2025
Emergent BioSolutions USD 381.2M 226.1M Jun/2023
Esperion Therapeutics USD 51.63M 22.2M Sep/2024
GlaxoSmithKline GBP 2.61B 377M Dec/2025
Heron Therapeutics USD 9.46M 1.61M Sep/2024
Insmed USD 46.16M 15.25M Dec/2025
Ligand Pharmaceuticals USD 11.9M 733K Sep/2025
Merck USD 3.32B 531M Dec/2025
Nektar Therapeutics USD 4.43M 5.3M Sep/2024
Neurocrine Biosciences USD 17.6M 246.4M Dec/2025
Omeros USD 33.16M 18.52M Jun/2024
Pacira USD 54.62M 6.02M Dec/2025
Regeneron Pharmaceuticals USD 584.6M 63M Dec/2025
Roche Holding CHF 8.48B 4.61B Dec/2025
Sangamo BioSciences 2.42M 1.11M Jun/2024
Surmodics USD 33.03M 24.58M Sep/2024
Ultragenyx Pharmaceutical USD 29M 1.01M Dec/2025
Veracyte USD 39.28M 1.93M Dec/2025
Vertex Pharmaceuticals USD 466M 51.2M Dec/2025